newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Update on Graves' Disease Development Program

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12Strong